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Abstract: Many biological barriers are of great importance. For example, stratum corneum, 
the outmost layer of skin, effectively protects people from being invaded by external 
microorganisms such as bacteria and viruses. Cell membranes help organisms maintain 
homeostasis by controlling substances to enter and leave cells.  However, on the other hand, 
these biological barriers seriously restrict drug delivery. For instance, stratum corneum has a 
very dense structure and only allows very small molecules with molecule weight of below 
500 Da to permeate while most drug molecules are much larger than that. A wide variety of 
drugs including genes need to enter cells for proper function but cell membranes are not 
permeable to them. To overcome these biological barriers, many drug delivery routes are 
being actively researched and developed. In this review, we will focus on two advanced 
materials and nanotechnology approaches for delivering vaccines through the skin for painless 
and efficient immunization and transporting drug molecules to cross cell membranes for high-
throughput intracellular delivery. 
 
1. Introduction 
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Humans are surrounded with endless hazardous agents like viruses, bacteria, gases, chemicals 
and physical agents. The fine and sophisticated biological barriers in the human body can 
strongly prevent the access of these hazardous agents into the human body and thus minimize 
the potential health risk towards humans. Epithelia of the skin, the gastrointestinal tract and 
the respiratory system are three anatomical primary barriers to isolate the human body from 
external environment.[1] For example, skin – the largest organ of the human body – contains 
three layers including stratum corneum, dermis, and hypodermis. The highly packed stratum 
corneum layer consisting of dead cells acts as a strict and powerful barrier to prevent external 
agents from invading the human body. While these powerful barriers effectively protect the 
human body from invading risk agents, they also block the routes for transdermal drug 
delivery, which is an alternative route for oral and parenteral administration and has 
tremendous advantages such as pain free, eliminating the first-pass effect, no needle stick 
injuries, no cross infection and high efficacy. However, the nature of the skin only allows 
very small molecules with a molecule weight of below 500 Da to permeate skin while most 
drug molecules are much larger than that.[2] Besides skin, there are also many other biological 
barriers which seriously limit delivery of drugs to desired sites, including mucosal membranes, 
the blood-brain barrier and the cell/nuclear membrane.[3] The cell membrane, the biological 
barrier that isolates and protect cell from outside environment, restricts intracellular delivery 
of drugs and biomolecules into the cell cytoplasm. These biological barriers seriously limit 
the delivery of drugs into the desired sites within the body, resulting in low delivery efficacy, 
poor therapeutic efficacy, and high cost. To address these issues, many biological, chemical 
and physical strategies have been developed to overcome the biological barriers for greatly 
improved drug delivery. Herein, we will highlight two of the recent advanced physical 
approaches for transdermal and intracellular delivery. 
 
2. Microneedle arrays for transdermal delivery 
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2.1. Silicon and metal microneedle arrays 
Needle and syringe injection has been widely used for delivering drugs and vaccines to the 
subcutaneous layer and muscle. Although working effectively, this approach has many 
shortcomings such as causing pain and leading to infection and needle stick injuries. To deal 
with the problems, a great alternative is to deliver drugs to skin for ultimate absorption into 
the systemic circulation. For this purpose, microneedle arrays are particularly attractive 
because of their simple administration, cheap cost, minimal invasive property and lower risk 
of infection.[4-8] At the early stage of the development, microneedle arrays were made of 
silicon and metals.[4, 5]  Silicon microneedle arrays were firstly reported in 1998 and they were 
fabricated through deep reactive ion etching (DRIE).[9, 10] These microneedles are often a few 
hundred micrometers in length and with very sharp tips to ensure reliable penetration into the 
epidermal and upper dermal layers of skin for drug delivery. With these solid microneedles, 
drugs are often dry-coated on their surface for subsequent delivery to the skin. Desirably, the 
coating should be mainly on the surface of the distal part of the microneedles because only 
this part can enter the skin during microneedle penetration (Figure 1a and 1b). Such coating 
is very challenging due to the micro-dimensions of the microneedles,[11] particularly for highly 
densely packed microneedles.[2]   To cope with this, various approaches have been developed 
for dry-coating a range of molecules to the surface of the microneedles. After coating, the dry-
coated microneedles can be applied to the skin and the coating will be dissolved in the wet 
cellular environment in the skin, indicated by the red signal in Figure 1c and 1d, within a short 
period of time, generally a few minutes.[2, 11-13]  The densely packed microneedles (over 
20,000 microneedles per cm2) were designed for “depositing antigen directly to high 
populations of antigen presenting cells residing within the skin layers” for ultimately 
dramatically improved vaccine efficacy.[14]  These microneedles can be applied to the skin by 
using a spring based applicator.[15] By controlling the application speed (strain rate), the 
penetration depth of a same microneedle patch to the skin can be controlled.[15] Due to the 
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high density, when the patch was applied to the skin by hand,[11, 16, 17] it led to variable and 
shallow penetration depth into the skin.[15] With patch application, a study showed that these 
densely packed microneedles were able to directly deposit antigen to more than 50% of the 
epidermal and dermal immune cells.[14] In Figure 1c, it can be clearly seen that the coating 
(red) has been transported to the vicinity of a great number of immune cells (green). Another 
study showed that, after microneedle delivery of vaccines, the number of the immune cells 
under the patched area displayed a dramatic reduction of 66% within one day.[18] This 
indicates the immune cells might have drained to the lymph nodes for generating immune 
responses. [18] When microneedle arrays were tested for vaccine delivery in animal models, in 
general, with reference to needle and syringe injection, it is possible to achieve improved 
immune responses with same doses of vaccines or similar immune responses with reduced 
doses. For example, when a Macroflux® microneedle array system (330 µm in length, 190 
microneedles per cm2, 1 cm2 in area) was used to deliver dry-coated ovalbumin (OVA) 
protein to hairless guinea pigs, at 1 and 5 µg doses, the microneedle administration induced 
immune responses of up to 50-fold greater than those observed after subcutaneous or 
intramuscular injection of the same doses, determined by the anti-OVA antibody titers.[19] 
When another type of densely packed microneedles (110 µm in length, over 20,000 
microneedles per cm2, 4x4 mm per patch, 2 patches per mouse) was used to deliver vaccines 
in mouse models and compared with intramuscular injection, to induce similar immune 
responses, the dose sparing was as high as over 100 and 10 folds for influenza vaccine[13, 14, 20]  
and HSV2-gD2 DNA vaccine,[21, 22]   respectively. Microneedle arrays have now been tested to 
be suitable for delivering a range of vaccines including ovalbumin protein,[12] human 
papillomavirus (HPV) vaccine (Gardasil® by Merck),[23] inactivated whole chikungunya virus 
vaccine, DNA-delivered attenuated west nile virus vaccine,[18] inactivated rotavirus 
vaccine,[24] hepatitis C DNA vaccine, [25] and Bacillus Calmette-Guerin vaccine.[26] Except 
vaccines, this technology has also been widely applied to deliver insulin,[27, 28] and 
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hormone.[29] Microneedle technology provides a non-invasive way for insulin delivery and 
requires minimal training. In addition, reports also show microneedles can help gene 
transfection and siRNA-based gene silencing.[30, 31] Overall, extensive results have 
demonstrated successful delivery of a wide range of biomolecules including proteins, DNA, 
fluorescent probes, viruses, virus-like-particles, drugs, hormones to skin, often with improved 
efficacy. In addition to enhanced efficacy and minimal pain, microneedles offer other 
advantages such as excellent thermostability at room temperature compared with liquid 
vaccine administrated by needle and syringe: influenza vaccine coated microneedle arrays 
remain stable for at least 6 months at 23 oC, indicated by its capacity of inducing statistically 
equivalent immunogenicity with freshly coated patches.[13] In contrast, the vaccine in liquid 
form has a shelf-life of only 14-20 weeks defined by having above 2/3 of the original 
hemagglutinin content remained.[32] The thermostability is very important for reducing cost of 
vaccination and for reaching areas lacking of “cold-chain” for vaccine storage and transport. 
It is believed that the addition of trehalose and viscosity enhancer in coating solution was 
beneficial to the improved stability.[33] 
2.2. Dissolvable polymer microneedle arrays 
Despite of great results of silicon and metal microneedle arrays for transdermal delivery, there 
are safety and cost concerns including: (1) the fabrication of these microneedles often requires 
expensive materials and production technologies such as deep reactive ion etching (DRIE) 
and laser cutting; and (2) the possible breakage of the small microneedles in skin leads to 
safety problems. To overcome these disadvantages, one approach is to choose biocompatible 
and biodegradable polymers as the materials for manufacturing microneedle arrays. Such 
microneedles may be designed to incorporate drugs/vaccines in the interior of the 
microneedles which can be rapidly dissolved within the skin during application for drug 
release.[16, 17, 34, 35]  Compared with dry-coated solid microneedle arrays, dissolvable ones have 
superior advantages including: 1) greater drug/vaccine loading capacity; 2) increased control 
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of release; 3) reduced cost and safety concern because cheap biocompatible and 
biodegradable materials and cost-effective molding technology can be used in fabrication.[34] 
This type of microneedle arrays was firstly reported by Prausnitz and co-workers in 2008. [35] 
In the work, microneedles were made using in-situ UV polymerization of monomeric vinyl 
pyrrolidone. This kind of microneedles had been used to deliver proteins,[35] influenza 
prophylaxis[36] and influenza vaccine.[36] For the influenza vaccine, it was found that robust 
antibody and cellular immune responses were generated. Carboxymethylcellulose (CMC) was 
also used to fabricate dissolving microneedle arrays.[15, 34, 37] Demuth et al. reported composite 
dissolving microneedles composed of ovalbumin vaccine and silk hydrogel tips for 
sustainable vaccine release. This technology demonstrates programmable 1-2 weeks vaccine 
release through which enhanced cellular and humoral immune responses were achieved.[38] 
Omenetto and co-workers also reported a type of dissolvable silk protein microneedles with 
tunable release kinetics.[39, 40]  
Although dissolvable microneedles possess many advantages and have been demonstrated to 
work effectively, these dissolvable polymers generally have relatively weak mechanical 
properties and it is highly desirable to improve their mechanical strength to ensure reliable, 
consistent and reproducible penetration in human skin for future practical applications. 
Currently, majority of the research was performed in mouse models, but human skin is 
mechanically much stronger and thicker than mouse skin. The weak mechanical strength of 
polyvinylpyrrolidone (PVP) microneedles had been attempted to be increased by forming 
poly(vinylpyrrolidone-co-methacrylic acid) (PVP-MAA) co-polymer microneedles. However, 
with the increase of the mechanical strength, the co-polymer microneedles dissolved much 
slower than the pure PVP ones. In comparison, it took PVP and PVP-MAA (25% of MAA) 
microneedles to dissolve within 15 min and 2 h, respectively.[35]  Very recently, we reported to 
add nanomaterials to a dissolvable polymer to greatly improve the mechanical properties but 
without sacrificing the dissolution rate in the skin. Figure 2a shows that the Young’s modulus 
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of CMC increases with the addition of layered double hydroxides (LDH) nanoparticles from 
0.993±0.065 (Sample “A”: pure polymer) to 1.489±0.036 (Sample “B”: 2% LDH) and 
2.878±0.123 (Sample “C”: 5% LDH) GPa. With the mechanically strengthened CMC-LDH 
nanocomposite, microneedle arrays with very sharp tips can be conveniently fabricated using 
molding technique (Figure 2b). During fabrication, it is possible to only incorporate 
drugs/vaccines to the microneedles while the base is only made of polymer (Figure 2c). In the 
figure, green fluorescence shows the surrogate of vaccines has been predominantly in the 
microneedles while the base is dark (non-fluorescent). Attractively, these microneedles can 
rapidly dissolve in the skin within only 1 minute after application (Figure 2d). Confocal 
microscopy images confirm that the microneedles can successfully pierce pig skin (Figure 2g) 
and deliver the incorporated fluorescent dyes to the skin (Figure 2h). More importantly, 
Figure 3a indicates that the CMC-LDH nanocomposite microneedles are capable to 
uniformly pierce pig skin across the whole patch area, while only the central part of the CMC 
microneedle patch can penetrate into skin (Figure 3b). Furthermore, even in the penetrated 
area, the penetration depth of nanomaterial strengthened microneedles is greater (71±7 v.s. 
46±12 µm for that created by pure CMC microneedles). The application of these 
microneedles on human skin was also performed with similar findings. In vaccination test in 
mouse model, microneedle arrays worked much better than needle and syringe injection. 
After primary immunization, subcutaneous injection of 20 µg of ovalbumin did not generate 
noticeable antibody titers while microneedle delivery induced already a very strong immune 
response (Figure 3c). If we compare pure CMC and CMC-LDH microneedles, it can be easily 
found that CMC-LDH microneedle delivery leads to stronger immune response with a lower 
dose (Figure 3d). The introduction of nanotechnology to strengthen dissolvable polymer 
microneedles can greatly increase the drug delivery efficacy and design flexibility and ensure 
the reliability of this transdermal delivery technique. In the long run, the nanomaterials may 
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also be used to aid gene delivery and DNA vaccination. This work is an important step toward 
using dissolvable microneedle arrays for potential use in clinical applications.[41]  
 
3. Nanoneedle arrays for intercellular delivery 
3.1 Nanowire arrays for passive penetration into cells for intracellular delivery 
Delivery of biomolecules (e.g., cell probes, genes, peptides, drugs, and proteins) into living 
cells is of great importance to not only basic cell biology but also medical applications. For 
example, gene and cell therapy is promising for curing many diseases which are otherwise 
difficult to be treated. In the therapy, genes such as DNA, siRNA, miRNA, and shRNA need 
to be delivered to cell cytoplasm or nuclei to be functional.[42-45]  It is also often neccessary to 
deliver fluorescent probes into cells for studying biological processes at molecular level inside 
living cells. However, these molecules have low capability of penetrating cell membranes 
because of a variety of reasons including large size, surface charge, instability, hydrophilicity, 
etc.[42, 43] Many efforts have been made to increase intracellular delivery efficacy using 
techniques such as viral vectors,[45, 46] cell-penetrating peptide vectors,[47] and nanoparticles.[48] 
Although these methods work effectively with some advantages, their wide applications are 
hindered by many limitations. For example, there are safety concerns for viral vectors[49, 50]. 
Nanomaterials and cell-penetrating peptides have the problems of cell-type specificity, 
limitation of in vivo applicability, and cytotoxicity.[51, 52]  Except these biological and chemical 
approaches, physical routes like microinjection and electroporation are also actively 
developed for intracellular delivery. However, microinjection is time consuming and requires 
expensive equipment and trained personnel and electroporation often leads to high cell 
toxicity. Kim et al. introduced using silicon nanowire (SiNW) arrays for intracellular delivery. 
In the work, HEK 293T cells were cultured on the SiNWs array pre-coated with plasmid GFP 
DNA. During cell culturing, the nanowires were able to pierce into cells and the pre-coated 
DNA was able to express protein.[53] Shalek et al. further demonstrated surface-modified 
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SiNWs which can be spatially localized for an efficient and universal delivery of 
biomolecules into immortalized and primary cells. Similarly, the cells also need to be cultured 
on the nanowires in order for them to pierce into cells for subsequent intracellular delivery. 
With this method, a wide range of biomedical applications can be achieved. For example, it is 
able to deliver small molecules to guide neuronal progenitor growth, siRNAs to knock down 
transcript levels, peptides to inhibit apoptosis, and introduce targeted proteins to specific 
organelles.[54] Recently, alumina hollow nanostraw arrays were fabricated, which can also 
penetrate into cells during culturing and then proteins and genetic materials are able to be 
injected into cells through an integrated device.[55] Also these hollow nanostraws can be 
equipped with nanoelectroporation platform to achieve highly efficient molecular delivery 
and high transfection yields with excellent uniformity and cell viability.[56] However, in all of 
these approaches, cells need to be cultured on the nanowires or nanostraws to allow them to 
be passively incorporated into cells for subsequent intracellular delivery of various molecules, 
drugs, genes and fluorescent probes. It is expected that it needs to take a relatively long period 
of time for cell culturing before intracellular delivery can be performed. The other issue is 
whether the cells in which intracellular delivery has been achieved by the technologies can be 
removed from the growing substrate and used for any further applications. 
3.2 Nanoneedle arrays to actively disrupt cell membranes for intracellular delivery  
Inspired by the success of employing microneedle arrays for drug delivery, we first reported 
using a nanoneedle array to actively and mechanically disrupt cell membranes for intracellular 
delivery. Transdermal and intracellular delivery has one common point. For transdermal 
delivery, the outmost layer of skin, stratum corneum limits the diffusion of most materials, 
molecules, genes and drugs to the skin. For intracellular delivery, cell membrane plays a 
similar role, so since microneedles can be used to pierce stratum corneum to make 
transdermal delivery achievable, one should be able to use a similar approach for intracellular 
delivery. However, if microneedles are applied to cells, due to their large geometry, cells 
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might be easily killed. Therefore, nanoneedles were designed for intracellular delivery. To 
allow the nanoneedles with an extremely small diameter to have enough strength to 
mechanically disrupt the cell membranes, we used diamond, the hardest material in nature, to 
produce the nanoneedle patch (Figure 4a).[57] This diamond nanoneedle array was fabricated 
by bias-assisted reactive ion etching (RIE) of a silicon substrate with a pre-deposited diamond 
film. Different from time-consuming culturing cells on SiNWs substrates, a suspension 
containing a large number of cells was rapidly applied onto the diamond nanoneedles. It is 
expected that the cell membranes will be disrupted during the process so high-throughput 
intracellular delivery is permitted. Figure 4b and 4c shows two groups of cells in which one 
group was treated by the nanoneedle array (Figure 4b) and the other group was left untreated. 
A luminescent iridium(III) polypyridine complex was added in the cell suspension. This 
luminescent complex is special because it shows negligible nuclear uptake.[58] The results 
show that nanoneedle treated cells display very strong fluorescence in the cytoplasm of cells 
(Figure 4b) while the untreated group shows very weak signal (Figure 4c). If we compare the 
fluorescence signals in the nuclei of the representative cells in the two groups after 
normalizing their fluorescence intensities in the cytoplasm to be the same value (Figure 4d 
and 4e), it is easy to find that there is much stronger fluorescence in the nuclei of the 
nanoneedle treated cells. Because the fluorescent probe is not able to enter the cell nucleus by 
diffusion, it is reasonable to conclude that the nanoneedle treatment has played an important 
role in aiding direct nucleus delivery. Other than using fluorescent probes, an anticancer drug, 
cisplatin, was also tested. Cisplatin needs to enter cells to effectively kill them. In the 
experiments, it was found that either nanoneedle array or 1 µM of cisplatin treatment led to 
negligible cancer cell death compared with untreated cells. In great contrast, the viability of 
the group of cells which was treated by both nanoneedles and 1 µM of cisplatin was 
dramatically dropped to 39.9±6.5% (Figure 4f). The corresponding optical images of the 
untreated cells and the 3 groups of cells which were treated under different conditions are 
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shown in Figure 5a-d. These images clearly demonstrate the stunning effect of the diamond 
nanoneedles in improving intracellular delivery. In another study, with similar mechanism, a 
densely packed diamond nanocone array was able to improve the delivery of differentiation 
medium to MC-3T3 cells to speed up their differentiation ability.[59] This novel technology of 
using nanoneedle/nanocone arrays for intracellular delivery has many superior advantages 
compared with prior approaches. It is expected to be convenient, highly efficient, high-
throughput, universal, safe and cost-effective. This facile approach paves the way for potential 
high-throughput delivery of genes, drugs and fluorescent probes into cells. 
 
4. Conclusion and outlook 
We have reviewed the recent advanced materials and nanotechnology development of drug 
delivery crossing biological barriers mainly including microneedle arrays for transdermal 
delivery and nanoneedle arrays for intracellular delivery. Microneedle arrays are expected to 
play a very important role in skin disease treatment, efficient vaccination and drug delivery. 
This technology possesses overwhelming advantages of being pain-free, reduced risk of 
infection and needle-stick injuries, ease of administration, improved efficacy, and minimal 
requirement of ‘cold-chain’ facility and trained personnel. The similar principle has now been 
extended for convenient, highly efficient, high-throughput, safe and universal intracellular 
delivery. For microneedle arrays for transdermal delivery, relatively systematic studies have 
been performed and a number of clinical trials are undergoing to bring the technology for 
clinical use. Further technological development will be needed to ensure the safety profile and 
further reduce the cost as well as increase the convenience. The approach of applying 
nanoneedle arrays for intracellular delivery is currently still at its starting stage. More 
systematic studies are required to demonstrate the advantages of the technology. In addition, it 
is essential to carry out researches to optimize the nanoneedle array manufacturing and design 
parameters for optimal and reproducible results. In summary, the purpose of this research 
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news is to highlight the important progress in the field of advanced materials and 
nanotechnology for drug delivery crossing biological barriers including microneedle arrays 
for transdermal delivery and nanoneedle ones for intracellular delivery. We hope to excite the 
interest to explore more solutions from advanced materials and nanotechnology perspective to 
overcome the difficulties which we are currently facing and to encourage more in vitro and in 
vivo studies, and clinical trials of drug delivery with the developed approaches. 
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Figure 1 (a) and (b) SEM images of silicon microprojections coated with ovalbumin (OVA) 
protein. The dark signal on the tips of microprojections indicates dry coated DNA vaccine 
which can be dissolved and released in the epidermal and dermal layers once the 
microprojections are inserted into skin. (c) and (d) Fluorescence microscopy images of the 
release of Cy5-OVA (red) from the microprojection patch applied to murine skin. The image 
shows a 0.176 μm2 region of the patched area consisting of 36 projections sites. MHC-II 
positive cells were stained using an FITC (green) stain. The second harmonic generation of 
collagen is also shown (blue). d) A cross-sectional view of six coating delivery sites. 
Colocalization of MHCII positive cells and rhodamine dextran is shown (arrow heads). 
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Figure 2 (a) Elastic modulus of CMC polymer films with different LDH concentrations: A) 0 
wt%; B) 2 wt%; D) 10 wt% and E) 5 wt% with centrifugation. (b) Scanning electron 
microscopy images of CMC-LDH nanocomposite dissolvable microneedles (inset: digital 
camera image of a polymer microneedle array). (c-f) Merged fluorescence and reflectance 
confocal microscopy images of CMC–LDH nanocomposite microneedles: c) before 
application, d) 1 min, e) 2 min, and f) 5 min after application to pig skin. (g-h) Laser scanning 
confocal microscopy images of pig skin after 5 min microneedle application; g: top view and 
h: z-view.  
 
Reproduced with permission.[Ref. 41] Copyright 2013, Publisher WILEY-VCH Verlag GmbH 
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Figure 3 (a-b) Reflectance confocal microscopy images of pig skin after 5 min CMC–LDH 
nanocomposite microneedle application. (c-d) Total ovalbumin lgG levels at 14 and 38 d after 
vaccination. Five mice were subcutaneously injected with 20 μg of OVA protein to be the 
positive control. Four unimmunized mice were negative control. For microneedle 
immunization, either pure CMC or CMC–LDH nanocomposite microneedle patches 
containing different amounts of OVA protein were used to vaccinate the mice. Each group has 
four mice. Mice were immunized at day 0 and boosted at day 17. At days 14 and 38, sera 
were collected and assayed for antibody titer measurements. The antibody titers at different 
dilutions of each group of mice were shown in the figure. 
 
Reproduced with permission.[Ref. 41] Copyright 2013, Publisher WILEY-VCH Verlag GmbH 
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Figure 4 (a) SEM image of diamond nanoprojections; (b) and (c) are the confocal microcopy 
images of diamond nanoneedles treated cells and untreated cells, respectively, after 19 hours 
incubation with luminescent iridium (III) polypyridine complex; (d) and (e) show the 
normalized emission intensity over the lines drawn crossing over cells in (b) and (c), 
respectively; The scale bars in (b), (c) indicate 25 μm. (f) The viability of cells at 72 hours 
post plating. The cells were treated with diamond nanoneedles, cisplatin or none or both. UT 
(shown in blue) and T (shown in red) indicate that the cells were untreated or treated with 
nanoneedles, respectively. UT1: the cells were treated by neither nanoneedles nor cisplatin; 
T1: the cells were treated with nanoneedles but not cisplatin; UT2: the cells were treated by 
cisplatin but not nanoneedles; T2: the cells were treated by both nanoneedles and cisplatin.  
 
Reproduced with permission.[Ref. 57] Copyright 2013, Publisher WILEY-VCH Verlag GmbH 
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Figure 5 Bright field images of cells at 72 hours post plating. (a) Cells were treated with 
neither diamond nanoneedles nor cisplatin (cDDP); (b) Cells were treated with diamond 
nanoneedles but not cisplatin; (c) Cells were treated with cisplatin but not diamond 
nanoneedles; and (d) Cells were treated with both diamond nanoneedles and cisplatin. 
 
Reproduced with permission.[Ref. 57] Copyright 2013, Publisher WILEY-VCH Verlag GmbH 
& Co. KGaA 
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The table of contents entry should be 50−60 words long (max. 400 characters), and the first 
phrase should be bold.  
Biological barriers including stratum corneum and cell membranes pose a difficulty in 
transdermal and intracellular delivery of fluorescent probes, biological molecules, genes, 
etc. Various approaches have been or are being developed for tackling the problem. Herein, 
we review the current state of applying advanced materials and nanotechnology for drug 
delivery crossing biological barriers by highlighting recently published novel and important 
results. 
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